^
Association details:
| Biomarker: | NRG1 overexpression + ERBB3 expression |
|---|---|
| Cancer: | Head and Neck Cancer |
| Drug: | lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers
Excerpt:
Next, we assessed NRG1 and HER3 mRNA levels in 29 primary head and neck cancer samples and compared the expression to the lapatinib-sensitive cell lines and a panel of 17 lapatinib-refractory cell lines (Figure 7C). All of the lapatinib-sensitive cell lines demonstrated relatively high levels of NRG1 mRNA expression, with coexpression of HER3 mRNA...
DOI:
10.1016/j.ccr.2011.07.011
